Heart Drug Trial Falls Short for HCM Patients

What Was Studied — and Why Diabetes Patients Should Pay Attention

Researchers conducted a large, rigorous clinical trial called ODYSSEY-HCM to test a heart medication called mavacamten in people with a condition known as non-obstructive hypertrophic cardiomyopathy (nHCM). This is a form of heart disease where the heart muscle becomes abnormally thick, making it harder to exercise and breathe — but without a specific blockage that doctors can easily target. People living with diabetes are at higher risk for heart complications, making this research especially relevant to the diabetes community.

What the Researchers Did

Over 400 adults with symptomatic nHCM were randomly assigned to receive either mavacamten — a drug that works by reducing the overactivity of a specific heart muscle protein — or a placebo (a dummy pill) for 48 weeks. Doses were carefully adjusted based on regular heart ultrasound (echocardiogram) scans. Researchers measured two main outcomes:

• How much oxygen patients could use during peak exercise (a measure of heart and lung fitness)
• How patients rated their own symptoms and quality of life using a validated questionnaire

What They Found

The results were mixed. On the positive side, mavacamten did show it was working inside the body — blood markers of heart stress went down, and heart imaging showed modest improvements in heart structure. This is called "target engagement," meaning the drug was hitting the right biological target.

However — and this is the important part — those biological changes did not translate into meaningful improvements in exercise capacity or how patients felt day to day. The drug did not meet its primary goals at the end of the 48-week study period.

There was also a safety concern: some patients experienced temporary drops in their heart's pumping strength (ejection fraction), requiring the drug to be paused. This suggests the drug has a narrow margin between a helpful dose and a potentially harmful one in this particular group of patients.

What This Means for Real Patients

If you or a loved one has been diagnosed with non-obstructive HCM — especially alongside diabetes — this trial is a reminder that promising science doesn't always immediately translate to better daily health. Mavacamten is not currently approved for this form of HCM, and this trial confirms that more work is needed.

Managing diabetes well remains one of the most powerful tools for protecting your heart. That means consistent blood sugar monitoring, taking medications as prescribed, and using the right supplies. MDS Diabetes carries a wide range of testing and monitoring supplies to help you stay on top of your daily diabetes management while your care team monitors your heart health.

Researchers are now calling for longer studies, trials with different dosing approaches, and enrolling patients who are more likely to respond — so future options may improve.

Bottom Line

Mavacamten showed it could affect heart biology in non-obstructive HCM patients, but failed to meaningfully improve exercise ability or quality of life in this trial. The drug also caused temporary heart function drops in some patients. More research with better-designed trials is needed before this treatment can be recommended. In the meantime, managing diabetes carefully — with consistent monitoring and the right supplies from trusted providers like MDS Diabetes — remains essential for protecting your heart health long term.